Skip to main content
    L

    Lifeward Ltd. (LFWD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $3.62
    -0.44 (-10.84%)

    Market Cap: $11.53M

    Last updated: Nov 17, 2026 at 10:42 AM ET

    Lifeward Ltd. (LFWD) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Lifeward (LFWD) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Lifeward reported EPS of -$1.32, below the -$0.53 estimate. It beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(14/39)
    Avg Surprise
    -53.14%

    Upcoming Estimates

    Reports Mar 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.71
    Range-$0.81 - -$0.60
    4 analysts
    Revenue Consensus
    $7.20M
    Range$6.10M - $8.28M
    4 analysts

    Next Report

    LFWD has an expected report date of Mar 16, 2027.

    LFWD Earnings Call

    The latest LFWD earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, LFWD beat 14, missed 23 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $5.43M, down 12.4% from $6.20M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.32-$0.53N/A-149.06%MissN/A10 up, 0 downNov 13, 2026$5.43M
    Jun 30, 2026-$1.46-$1.49N/A+2.01%BeatN/A10 up, 0 downAug 14, 2026$6.62M
    Mar 31, 2026-$6.70-$0.34-$0.34 - -$0.34N/AN/AN/A11 up, 0 downMay 15, 2026$3.92M
    Dec 31, 2025-$2.85-$1.08-$1.08 - -$1.08-163.89%MissN/A10 up, 0 downMar 18, 2026$5.08M
    Sep 30, 2025-$2.28-$1.92N/A-18.75%MissN/A10 up, 0 downNov 14, 2025$6.20M
    Jun 30, 2025-$3.72-$2.88-$2.88 - -$2.88-29.17%MissN/A10 up, 0 downAug 14, 2025$5.72M
    Mar 31, 2025-$0.46-$0.33-$0.33 - -$0.24-39.39%MissN/A20 up, 0 downMay 15, 2025$5.03M
    Dec 31, 2024-$0.38-$0.33-$0.33 - -$0.33-15.15%MissN/A11 up, 0 downMar 7, 2025$7.54M
    Sep 30, 2024-$4.20-$3.78-$4.32 - -$3.24-11.11%MissN/A22 up, 0 downNov 12, 2024$6.13M
    Jun 30, 2024-$6.00-$6.60N/A+9.09%BeatN/AN/AN/AAug 14, 2024$6.71M
    Mar 31, 2024-$7.44-$8.40N/A+11.43%BeatN/AN/AN/AMay 15, 2024$5.28M
    Dec 31, 2023-$4.20-$9.24N/A+54.55%BeatN/AN/AN/AFeb 27, 2024$6.88M
    Sep 30, 2023-$6.72-$8.40N/A+20.00%BeatN/AN/AN/ANov 14, 2023$4.40M
    Jun 30, 2023-$5.29-$5.88N/A+10.03%BeatN/AN/AN/AAug 11, 2023$1.34M
    Mar 31, 2023-$5.67-$6.72N/A+15.63%BeatN/AN/AN/AMay 11, 2023$1.23M
    Dec 31, 2022-$7.56-$5.88N/A-28.57%MissN/AN/AN/AFeb 23, 2023$2.18M
    Sep 30, 2022-$7.56-$5.04N/A-50.00%MissN/AN/AN/ANov 7, 2022$886000
    Jun 30, 2022-$5.88-$3.36N/A-75.00%MissN/AN/AN/AAug 9, 2022$1.57M
    Mar 31, 2022-$5.57-$4.20N/A-32.62%MissN/AN/AN/AMay 13, 2022$876000
    Dec 31, 2021-$5.04-$3.36N/A-50.00%MissN/AN/AN/AFeb 24, 2022$1.24M
    Sep 30, 2021-$5.04-$5.04N/A0.00%In lineN/AN/AN/ANov 10, 2021$1.97M
    Jun 30, 2021-$5.88-$5.04N/A-16.67%MissN/AN/AN/AAug 9, 2021$1.44M
    Mar 31, 2021-$6.55-$5.88N/A-11.39%MissN/AN/AN/AMay 11, 2021$1.32M
    Dec 31, 2020-$11.76-$11.76N/A0.00%In lineN/AN/AN/AFeb 18, 2021$1.22M
    Sep 30, 2020-$15.12-$13.44N/A-12.50%MissN/AN/AN/ANov 10, 2020$747000
    Jun 30, 2020-$18.48-$22.68N/A+18.52%BeatN/AN/AN/AAug 12, 2020$1.67M
    Mar 31, 2020-$2.59-$0.26N/A-896.15%MissN/AN/AN/AMay 28, 2020$760000
    Dec 31, 2019-$41.16-$30.24N/A-36.11%MissN/AN/AN/AFeb 20, 2020$1.18M
    Sep 30, 2019-$38.64-$37.80N/A-2.22%MissN/AN/AN/ANov 13, 2019$1.23M
    Jun 30, 2019-$73.92-$41.16N/A-79.59%MissN/AN/AN/AAug 8, 2019$877000
    Mar 31, 2019-$105.00-$84.00N/A-25.00%MissN/AN/AN/AMay 7, 2019$1.58M
    Dec 31, 2018-$210.00-$294.00N/A+28.57%BeatN/AN/AN/AFeb 8, 2019$1.58M
    Sep 30, 2018-$273.00-$294.00N/A+7.14%BeatN/AN/AN/ANov 8, 2018$1.62M
    Jun 30, 2018-$378.00-$336.00N/A-12.50%MissN/AN/AN/AAug 14, 2018$1.77M
    Mar 31, 2018-$36.75-$38.49N/A+4.52%BeatN/AN/AN/AMay 10, 2018$1.58M
    Dec 31, 2017-$422.73-$546.00N/A+22.58%BeatN/AN/AN/AMar 8, 2018$1.51M
    Sep 30, 2017-$462.21-$735.00N/A+37.11%BeatN/AN/AN/ANov 2, 2017$1.73M
    Jun 30, 2017-$602.39-$805.00N/A+25.17%BeatN/AN/AN/AAug 3, 2017$2.01M
    Mar 31, 2017-$68.25-$10.08N/A-577.08%MissN/AN/AN/AMay 4, 2017$2.50M
    Dec 31, 2016-$997.29-$934.50N/A-6.72%MissN/AN/AN/AFeb 17, 2017$1.59M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$9.31, after -$18.02 the year before. It was -$4,443.41 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$9.31N/A
    Dec 31, 2024-$18.02N/A
    Dec 31, 2023-$21.88N/A
    Dec 31, 2022-$26.57N/A
    Dec 31, 2021-$22.51N/A
    Dec 31, 2020-$47.95N/A
    Dec 31, 2019-$258.72N/A
    Dec 31, 2018-$897.75N/A
    Dec 31, 2017-$1,555.58N/A
    Dec 31, 2016-$4,443.41N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,800 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20262,7675
    2025Q3Sep 30, 20253,9775
    2025Q2Jun 30, 20255,5396
    2025Q1Mar 31, 20255,6586
    2024Q4Dec 31, 20244,8986
    2024Q3Sep 30, 20245,6446
    2024Q2Jun 30, 20244,1395

    2026Q1 Earnings Call

    Opening remarks

    Almog Adar CFO Thank you, Drew, and thanks, everyone, who has joined us on the call today. My name is Almog Adar, I'm Lifeward's Chief Financial Officer. And with me on today's call is our President and Chief Executive Officer, Mark Grant. Earlier this morning, Lifeward issued a press release detailing the financial results for the first quarter ended March 31, 2026. I would ask you to review the full text of our forward-looking statements from the press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. With that, I will turn the call over to Mark.

    Mark Grant President & Chief Executive Officer Thank you, Almog, and thank you for everybody for joining us today. The first quarter of 2026 marked an important strategic milestone for Lifeward as we successfully completed the acquisition of Oratech. We believe this transaction significantly strengthens Lifeward's position as a diversified biomedical innovation company while reinforcing our focus on neurorehabilitation and our path toward profitability. We believe this was a highly strategic and capital-efficient transaction for Lifeward shareholders. Through the equity-based acquisition of Oratech, we gained access to the protein oral delivery platform, a potentially transformative technology across many therapeutic indications, including ORMD-0801 oral insulin, which is expected to commence a Phase II study. Importantly, the clinical program management responsibilities remain with Oramed, utilizing funds previously transferred to Oratech as part of the strategic transaction. That means Lifeward and our shareholders by owning the protein orally delivered platform outright effectively receive a meaningful option on the potential success of the promising technology with minimal near-term operational burden, no material increase in operating expenses and limited management bandwidth requirements beyond my own involvement, supporting strategic oversight and development guidance. As many of you know, my background includes extensive experience in diabetes and metabolic disease, and I believe this platform has meaningful long-term potential. At the same time, Lifeward's core focus remains firmly centered on scaling our neurorehabilitation MedTech business. The second key takeaway from the quarter is Lifeward is now substantially better positioned on its path to profitability. With the $10 million from our convertible note financing, we have significantly strengthened our balance sheet and improved our operating flexibility. This allows us to stabilize and build upon the fundamental and foundational work we have done over the last several quarters, while maintaining our disciplined focus on operational efficiency, market access and innovation across our neurorehabilitation platform. We expect continued operational stabilization over the next several quarters as our baseline resets following our manufacturing transition initiatives completed over the last year and the consummation of the important transaction this quarter.

    Frequently Asked Questions About LFWD

    When is Lifeward's next earnings date?

    Lifeward's next earnings report is expected for Mar 16, 2027.

    Did LFWD beat earnings estimates last quarter?

    No. Lifeward reported EPS of -$1.32 for the quarter ended Sep 30, 2026, below the -$0.53 estimate by 149.06%.

    What EPS do analysts expect from LFWD next quarter?

    The consensus EPS estimate for Lifeward for the quarter ending Dec 31, 2026 is -$0.71 from 4 analysts, with estimates from -$0.81 to -$0.60.

    How often does LFWD beat earnings estimates?

    Lifeward beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate, with an average surprise of -53.06%.